Rathbones Group PLC lessened its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 1.3% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 460,359 shares of the medical equipment provider's stock after selling 6,140 shares during the period. Intuitive Surgical comprises 1.1% of Rathbones Group PLC's investment portfolio, making the stock its 24th biggest holding. Rathbones Group PLC owned about 0.13% of Intuitive Surgical worth $228,002,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in ISRG. AlphaCore Capital LLC grew its position in shares of Intuitive Surgical by 4.2% during the fourth quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock worth $235,000 after buying an additional 18 shares in the last quarter. Second Line Capital LLC grew its position in shares of Intuitive Surgical by 3.4% during the fourth quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock worth $302,000 after buying an additional 19 shares in the last quarter. Colonial Trust Co SC grew its position in shares of Intuitive Surgical by 8.8% during the fourth quarter. Colonial Trust Co SC now owns 246 shares of the medical equipment provider's stock worth $128,000 after buying an additional 20 shares in the last quarter. Crown Wealth Group LLC grew its position in shares of Intuitive Surgical by 4.8% during the first quarter. Crown Wealth Group LLC now owns 440 shares of the medical equipment provider's stock worth $218,000 after buying an additional 20 shares in the last quarter. Finally, FSM Wealth Advisors LLC boosted its holdings in Intuitive Surgical by 3.8% in the first quarter. FSM Wealth Advisors LLC now owns 546 shares of the medical equipment provider's stock worth $270,000 after purchasing an additional 20 shares during the period. Institutional investors and hedge funds own 83.64% of the company's stock.
Insider Buying and Selling
In related news, SVP Mark Brosius sold 216 shares of the business's stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $563.11, for a total value of $121,631.76. Following the completion of the sale, the senior vice president directly owned 907 shares in the company, valued at approximately $510,740.77. The trade was a 19.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Gary S. Guthart sold 2,800 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $495.24, for a total value of $1,386,672.00. Following the completion of the sale, the insider owned 18,520 shares of the company's stock, valued at approximately $9,171,844.80. This trade represents a 13.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,839 shares of company stock worth $7,896,972. 0.70% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
ISRG has been the subject of a number of research reports. Piper Sandler reaffirmed an "overweight" rating and issued a $595.00 price objective (up previously from $575.00) on shares of Intuitive Surgical in a report on Wednesday, July 23rd. Truist Financial lifted their price objective on shares of Intuitive Surgical from $590.00 to $600.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Wells Fargo & Company lifted their price objective on shares of Intuitive Surgical from $559.00 to $599.00 and gave the stock an "overweight" rating in a report on Wednesday, July 23rd. Robert W. Baird reduced their price target on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. Finally, Citigroup reissued a "buy" rating and set a $650.00 price target (up previously from $590.00) on shares of Intuitive Surgical in a report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $595.95.
View Our Latest Analysis on ISRG
Intuitive Surgical Stock Performance
Shares of NASDAQ ISRG traded up $3.18 during trading hours on Friday, hitting $480.26. The stock had a trading volume of 1,433,726 shares, compared to its average volume of 1,995,639. The company has a market capitalization of $172.16 billion, a P/E ratio of 66.98, a P/E/G ratio of 5.06 and a beta of 1.59. The firm's 50-day moving average price is $510.29 and its two-hundred day moving average price is $526.13. Intuitive Surgical, Inc. has a 52 week low of $425.00 and a 52 week high of $616.00.
Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, topping the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%. The firm had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. During the same period in the previous year, the company earned $1.78 EPS. The company's revenue for the quarter was up 21.4% on a year-over-year basis. As a group, analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.
About Intuitive Surgical
(
Free Report)
Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.
Further Reading

Before you consider Intuitive Surgical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intuitive Surgical wasn't on the list.
While Intuitive Surgical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.